Discover novel case studies on the latest challenges and innovations in inhaled therapy formulation and device development, with in-depth presentations focusing on alternative therapeutic areas and advancements in combination products
Over 150 delegates from the inhalation, formulation and drug delivery industry representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and research institutions.
Over 20 presentations and case studies focusing on the emerging therapies and key issues in inhalation and respiratory drug delivery as well as the latest developments in medical devices and digital health products.
View Agenda: https://bit.ly/35dZ8hc
Co-located with the 6th Annual Formulation and Drug Delivery Congress and Biomanufacturing Congress.
For more information contact firstname.lastname@example.org or visit the website: https://bit.ly/2KFgtrv
Go Social: Join our Formulation and Drug Delivery Network on LinkedIn, follow us on Twitter @FDDCongress and join the conversation at #FDDUK20
*2020 Live Webinar*
Inhaled Targeted-Inhibition Of Galectin-3 Dose Dependently Blocks Plasma Biomarkers In Patients With Idiopathic Pulmonary Fibros
Tue, Mar 3, 2020 2:00 PM - 3:00 PM GMT
Presented by Tariq Sethi, Co-Founder, Galacto Biotech and Former Chief Scientist Vice President Clinical Development Unit, AstraZeneca
Register (free): https://bit.ly/37NpwAv
Registration Available from (+ VAT): GBP 520.00
Speakers: John Patton, President and Chief Executive Officer, Dance Pharmaceuticals, Mark Milton-Edwards, Head of Product and Health Solutions -Digital Health, Teva, Camilla Foged, Professor of Vaccine Design and Delivery, University of Copenhagen, Guilherme Safioti, Global Medical Director, Teva Digital Respiratory, Teva, Hlack Mohammed, Analytical Science and Technology Director, GlaxoSmithKline, Nico Ghilardi, Associate Director and Principal Scientist, Genentech, Michelle Dawson, Project Lead, GlaxoSmithKline